000156834 001__ 156834
000156834 005__ 20240229133505.0
000156834 0247_ $$2doi$$a10.1007/s00520-020-05580-0
000156834 0247_ $$2pmid$$apmid:32556623
000156834 0247_ $$2ISSN$$a0941-4355
000156834 0247_ $$2ISSN$$a1433-7339
000156834 0247_ $$2altmetric$$aaltmetric:97012709
000156834 037__ $$aDKFZ-2020-01151
000156834 041__ $$aeng
000156834 082__ $$a610
000156834 1001_ $$0P:(DE-He78)e0edc48464c2d5afd09687075ebd532b$$aKreutz, Charlotte$$b0$$eFirst author$$udkfz
000156834 245__ $$aComparison of subjectively and objectively assessed sleep problems in breast cancer patients starting neoadjuvant chemotherapy.
000156834 260__ $$aNew York,NY$$bSpringer$$c2021
000156834 3367_ $$2DRIVER$$aarticle
000156834 3367_ $$2DataCite$$aOutput Types/Journal article
000156834 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1611562100_13973
000156834 3367_ $$2BibTeX$$aARTICLE
000156834 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000156834 3367_ $$00$$2EndNote$$aJournal Article
000156834 500__ $$a#EA:C110#LA:C110#2021 Feb;29(2):1015-1023
000156834 520__ $$aTo characterize sleep problems and to compare subjective and objective assessments in breast cancer patients starting neoadjuvant chemotherapy.Sleep characteristics of 54 breast cancer patients starting neoadjuvant chemotherapy were analyzed. Subjective sleep characteristics were assessed with the Pittsburgh Sleep Quality Index (PSQI) and objective sleep measurements with an accelerometer (ActiGraph wGT3X-BT) worn on the wrist for 7 consecutive days.According to the common PSQI cut-off of 8, 10 (18.87%) of the patients were poor sleepers. ActiGraph measures did not mirror this classification as values for poor, and good sleepers did not differ significantly. Overall, Bland-Altman plots illustrated higher ActiGraph values for sleep efficiency and effective sleep time and lower values for sleep latency, compared with PSQI. For total sleep time, less disagreement between both measures was observed. Actigraphy was limited in precise identification of sleep begin and sleep latency but provided supplementary information about number and minutes of awakenings during the night.Subjective and objective measurement methods differed substantially in various parameters, with limitations in both methods. A combination of both methods might be most promising.Clinicaltrials.gov: NCT02999074.
000156834 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000156834 588__ $$aDataset connected to CrossRef, PubMed,
000156834 7001_ $$0P:(DE-He78)8e71a2b8353ffbcbcf57a748f7185461$$aMüller, Jana$$b1
000156834 7001_ $$0P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aSchmidt, Martina E$$b2$$udkfz
000156834 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b3$$eLast author$$udkfz
000156834 773__ $$0PERI:(DE-600)1463166-0$$a10.1007/s00520-020-05580-0$$n2$$p1015-1023$$tSupportive care in cancer$$v29$$x0941-4355$$y2021
000156834 909CO $$ooai:inrepo02.dkfz.de:156834$$pVDB
000156834 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e0edc48464c2d5afd09687075ebd532b$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000156834 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8e71a2b8353ffbcbcf57a748f7185461$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000156834 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000156834 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000156834 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000156834 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000156834 9141_ $$y2021
000156834 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2020-01-15$$wger
000156834 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2020-01-15$$wger
000156834 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-15
000156834 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-15
000156834 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-15
000156834 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-15
000156834 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-01-15
000156834 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index$$d2020-01-15
000156834 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-15
000156834 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-15
000156834 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-15
000156834 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSUPPORT CARE CANCER : 2018$$d2020-01-15
000156834 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-01-15
000156834 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-01-15
000156834 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-01-15
000156834 9202_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x0
000156834 9200_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x0
000156834 9201_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x0
000156834 980__ $$ajournal
000156834 980__ $$aVDB
000156834 980__ $$aI:(DE-He78)C110-20160331
000156834 980__ $$aUNRESTRICTED